FINWIRES · TerminalLIVE
FINWIRES

キントール・ファーマシューティカルの2026年の売上高は2025年の通年水準を上回る見込み

By

-- キントール・ファーマシューティカル(香港証券取引所:9939)は、2026年初頭からの売上高が2025年通期の売上高を上回ったと発表した。これは、B2CおよびB2B事業の力強い成長によるものだと、月曜日に香港証券取引所に提出した書類で明らかにした。 同社の株価は火曜日の午前中の取引で約2%上昇した。 同社によると、年初からの売上高は約3,400万元に達し、昨年の通期売上高3,270万元を上回った。 キントールは、これらの事業から得られるキャッシュフローを、主力医薬品パイプラインの開発と商業化に充てる計画だと述べた。

Related Articles

Asia

Biocytogen Pharmaceuticals Turns to Profit in Q1

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.

$HKG:2315
Oil & Energy

Market Chatter: LNG Carrier Orders Surge as Global Output Defies Iran War Tensions

Global demand for liquefied natural gas carriers is rebounding sharply in 2026, despite the ongoing US-Iran conflict, Reuters reported Monday, citing analysts and industry experts.Analysts report that surging LNG production and a transition toward high-efficiency vessels are fueling the recovery.According to the report, Shipbuilders in South Korea and China have already secured 35 new build contracts in Q1 alone.The resurgence in construction comes despite the escalating US-Iran war, which has choked the Strait of Hormuz and raised fears of a prolonged shipping downturn.However, market experts suggest that the need for modern, fuel-efficient tonnage is outweighing immediate freight rate concerns, it said.These new vessels, which cost between $250 million and $260 million and take over three years to complete, are increasingly necessary as older, steam-propelled tankers are scrapped at record rates to meet stricter global emissions regulations.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Research

Canaccord Genuity Initiates Coverage on Structure Therapeutics With Buy Rating, $101 Price Target

Structure Therapeutics (GPCR) has an average rating of Buy and mean price target of $108.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$GPCR